Fundamental studies on the mechanism of action of a novel sirtuin inhibitor (BZD9L 1) in colorectal cancer cells- towards the elucidation of a novel cancer therapeutic agent.

Loading...
Thumbnail Image
Date
2016
Authors
Chern Ein, Oon
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Gemcitabine remains the standard treatment for pancreatic cancer. although most patients acquire resistance to the therapy. Up-regulated in pancreatic cancer. SIRTI is involved in tumorigenesis and drug resistance, However the mechanism through which SIRTl regulates drug sensitivity in cancer cells is mainly unknown.
Description
Keywords
novel sirtuin inhibitor , cancer therapeutic
Citation